SOFIE And GE HealthCare Enter Licensing Agreement To Develop FAP PET Radiotracers
Portfolio Pulse from Benzinga Newsdesk
SOFIE Biosciences and GE HealthCare have entered into a global licensing agreement for the development and commercialization of SOFIE's two investigational radiopharmaceutical diagnostics. GE HealthCare will take on global rights for [68Ga]FAPI-46 and outside-US rights for [18F]FAPI-74, both currently in Phase II clinical trials. SOFIE will maintain clinical development and commercialization rights for [18F]FAPI-74 in the U.S.
October 11, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GE HealthCare, a division of General Electric, has entered into a global licensing agreement with SOFIE Biosciences. This could potentially expand GE's portfolio in radiopharmaceutical diagnostics.
The agreement allows GE HealthCare to develop and commercialize SOFIE's investigational radiopharmaceutical diagnostics globally, which could potentially expand its product portfolio and increase its market share in this sector.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100